Papa Alfredo, Scaldaferri Franco, Vetrone Lorenzo Maria, Neri Matteo, Gasbarrini Antonio, Lopetuso Loris Riccardo
CEMAD Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Vaccines (Basel). 2021 Mar 12;9(3):248. doi: 10.3390/vaccines9030248.
The severity of the COVID-19 pandemic has led to an unprecedented effort to develop vaccines against SARS-CoV-2 infection since this seems to be the most effective strategy to counter the pandemic. In the past weeks, the administration of vaccines has started in different parts of the world sustaining the hype of significantly containing the impact of SARS-CoV-2 infection. However, the rapid time lapse from vaccine development to distribution has raised several concerns on its safety and efficacy. This topic is particularly felt by patients with chronic conditions and immumodulating therapies that could compromise their immune system such as inflammatory bowel disease (IBD). Here, we explore the potential future implications of the SARS-CoV-2 vaccines introduction in the IBD field, touching upon the clinical experience coming from available data on vaccinations against other infections. We also dissect the factors associated with the acceptability of SARS-CoV-2 vaccination, describing the possible strategies that gastroenterologist should adopt to reach the highest rate of vaccinations in IBD patients.
新冠疫情的严重性促使人们为研发针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的疫苗做出了前所未有的努力，因为这似乎是对抗该疫情最有效的策略。在过去几周里，全球不同地区已开始接种疫苗，这进一步助长了人们对显著控制SARS-CoV-2感染影响的高度期待。然而，从疫苗研发到分发的时间间隔很短，这引发了人们对其安全性和有效性的诸多担忧。患有慢性病以及正在接受可能损害其免疫系统的免疫调节治疗（如炎症性肠病（IBD））的患者对此尤为担忧。在此，我们探讨SARS-CoV-2疫苗引入IBD领域可能产生的未来影响，并提及来自其他感染疫苗接种现有数据的临床经验。我们还剖析了与SARS-CoV-2疫苗接种可接受性相关的因素，描述了胃肠病学家为使IBD患者获得最高接种率应采取的可能策略。
